Revelation Biosciences, which announced in October 2020 that the TGA had approved plans for a Phase 1 study of its REVTx‑99 intranasal phosphorylated hexaacylated disaccharide (PHAD), said that it has now initiated the trial. According to the company, 8 healthy volunteers have already received either REVTx-99 or placebo in the single ascending dose study, which is expected to enroll a total of 32 subjects. Topline data are expected to be available in early 2021.
The nasal spray is in development for the prevention and treatment of respiratory viral infections, including SARS‑CoV‑2, and Revelation said that it plans to initiate a Phase 2 study in COVID-19 patients at risk of being hospitalized in the first half of 2021.
Revelation CEO James Rolke commented, “We are excited to have initiated the Phase 1 study and pleased to have completed rapid enrollment of the first cohort. We are grateful for the continued support of our clinical trial site and study participants, as we all manage through the global pandemic. We look forward to sharing data from all cohorts early next year.”
Read the Revelation Biosciences press release.
